Ascendis Pharma A/S

SecurityASND / Ascendis Pharma A/S
InstitutionStifel Financial Corp
Latest Disclosed Ownership19,597 shares
Latest Disclosed Value $ 4,482,426
Stifel Financial Corp reports 2.98% decrease in ownership of ASND / Ascendis Pharma A/S

On May 12, 2026 - Stifel Financial Corp filed a 13F-HR form disclosing ownership of 19,597 shares of Ascendis Pharma A/S (US:ASND) valued at $4,482,422 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 20,198 shares of Ascendis Pharma A/S. This represents a change in shares of -2.98% during the quarter. The current value of the position is $4,124,189 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 19,597 -601 -2.98 4,482 4.06 0.0010
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 20,198 -176 -0.86 4,307 6.35 0.0039
2025-11-12 2025-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 20,374 404 2.02 4,051 17.53 0.0037
2025-08-14 2025-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 19,970 3,874 24.07 3,447 37.40 0.0034
2025-05-14 2025-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 16,096 -1,001 -5.85 2,509 6.59 0.0027
2025-02-13 2024-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 17,097 4,534 36.09 2,354 25.49 0.0025
2024-11-14 2024-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 12,563 -544 -4.15 1,876 4.92 0.0020
2024-08-13 2024-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 13,107 -53 -0.40 1,788 -10.16 0.0020
2024-05-14 2024-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 13,160 579 4.60 1,989 25.57 0.0023
2024-02-12 2023-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 12,581 -12 -0.10 1,585 34.35 0.0020
2023-11-13 2023-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 12,593 2,941 30.47 1,179 36.93 0.0017
2023-08-14 2023-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 9,652 484 5.28 861 -12.32 0.0012
2023-05-12 2023-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 9,168 -205 -2.19 983 -14.16 0.0014
2023-02-13 2022-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 9,373 586 6.67 1,145 26.13 0.0017
2022-11-14 2022-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 8,787 497 6.00 907 17.64 0.0015
2022-08-15 2022-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 8,290 12 0.14 771 -20.68 0.0012
2022-05-13 2022-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 8,278 -165 -1.95 972 -14.44 0.0013
2022-02-14 2021-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 8,443 954 12.74 1,136 -4.86 0.0015
2021-11-15 2021-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 7,489 962 14.74 1,194 39.00 0.0018
2021-08-13 2021-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 6,527 -89 -1.35 859 0.70 0.0013
2021-05-14 2021-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 6,616 -42 -0.63 853 -23.15 0.0014
2021-02-12 2020-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 6,658 -56 -0.83 1,110 7.14 0.0020
2020-11-16 2020-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 6,714 268 4.16 1,036 8.71 0.0021
2020-08-14 2020-06-30 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 6,446 -335 -4.94 953 25.07 0.0022
2020-05-14 2020-03-31 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 6,781 69 1.03 762 -18.33 0.0021
2020-02-13 2019-12-31 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 6,712 2,509 59.70 933 129.24 0.0019
2019-11-19 2019-09-30 13F/A-1 ASCENDIS PHARMA A S SPONSORED ADR 04351P101 4,203 1,616 62.47 407 37.97 0.0010
2019-11-13 2019-09-30 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 4,203 1,616 407 228.1439
2019-08-14 2019-06-30 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 2,587 -147 -5.38 295 -8.67 0.0008
2019-05-14 2019-03-31 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 2,734 2,734 323 0.0009
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.